Telpegfilgrastim clinical trials
Its developmentBy Xiamen Amoytop Biotech, step by step2 company-led studies, furthest phase 1: when each phase was reached, its deals, target and what is ahead.How each study uses telpegfilgrastim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the telpegfilgrastim studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Xiamen Amoytop Biotech Co., Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Sun Yat-sen University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test telpegfilgrastim.
- Apr 2027Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid TumorsPhase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Studies
Open first, then newest update. How each study uses telpegfilgrastim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06926751Written as Telpegfilgrastim Injection
- Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with ChemotherapyRecruitingPhase 2Sun Yat-sen UniversityNCT06857292Written as Telpegfilgrastim
- Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of ChildbearingCompletedPhase 1Xiamen Amoytop Biotech Co., Ltd.NCT06924385Written as Telpegfilgrastim Injection
- Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant FemalesCompletedPhase 1Xiamen Amoytop Biotech Co., Ltd.NCT06893796Written as Telpegfilgrastim Injection
Codes
What other systems call telpegfilgrastim · ClinicalTrials.gg INT018193
- UNII (FDA) V2ZD052TS1TELPEGFILGRASTIMOne source FDA
- NCI Thesaurus C175860TelpegfilgrastimOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V2ZD052TS1 | TELPEGFILGRASTIM | One source FDA |
| NCI Thesaurus | C175860 | Telpegfilgrastim | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.